Journal of clinical gastroenterology · 2004
Is there any relationship between hepatitis C virus and vitiligo?
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Akbayir Nihat, Gökdemir Gonca, Mansur Tülin, Sökmen Mehmet, Gündüz Sevil, Alkim Canan, Barutcuoglu Burcu, Erdem Levent
Аннотация
GOALS AND BACKGROUND: Hepatitis C virus (HCV) is a hepatotropic and lymphotropic virus. This agent can promote development of a panel of autoimmune diseases. The relationship between HCV infection and vitiligo, in which autoimmune mechanisms are believed to play a role is not yet elucidated. In this study we investigated HCV seropositivity in vitiligo patients and compared this with non-vitiligo population.
STUDY: A total of 102 consecutive patients with vitiligo were included in the study (47 male, 55 female, mean age: 36.8 +/- 16.9 years, range: 5-75). Control population was 670 age and sex matched healthy blood donors (406 male, 264 female, mean age: 32.8 +/- 11.3 years, range: 20-58). Third generation enzyme immunoassay was used for serum anti-HCV determination. When positive, qualitative confirmation was performed by HCV-RNA determination using RT-PCR.
RESULTS: Anti-HCV antibody was detected only in 1 patient and confirmed by RT-PCR test. This patient was a 6-year-old girl with a non-segmental form of vitiligo, which is more frequently associated with autoimmune disorders, hence the incidence of HCV seropositivity found as 0.98%. There was no statistically significant difference between this figure and 0.6% prevalence in healthy blood donors.
CONCLUSION: Seroprevalence of HCV in vitiligo patients is not different from that of a control group in Turkey, and HCV infection may not be involved in the pathogenesis of vitiligo despite case reports showing co-existence of these 2 diseases.
STUDY: A total of 102 consecutive patients with vitiligo were included in the study (47 male, 55 female, mean age: 36.8 +/- 16.9 years, range: 5-75). Control population was 670 age and sex matched healthy blood donors (406 male, 264 female, mean age: 32.8 +/- 11.3 years, range: 20-58). Third generation enzyme immunoassay was used for serum anti-HCV determination. When positive, qualitative confirmation was performed by HCV-RNA determination using RT-PCR.
RESULTS: Anti-HCV antibody was detected only in 1 patient and confirmed by RT-PCR test. This patient was a 6-year-old girl with a non-segmental form of vitiligo, which is more frequently associated with autoimmune disorders, hence the incidence of HCV seropositivity found as 0.98%. There was no statistically significant difference between this figure and 0.6% prevalence in healthy blood donors.
CONCLUSION: Seroprevalence of HCV in vitiligo patients is not different from that of a control group in Turkey, and HCV infection may not be involved in the pathogenesis of vitiligo despite case reports showing co-existence of these 2 diseases.